Top Markets
Coin of the day
HLS Therapeutics Inc. HLS Therapeutics Inc.

HLS Therapeutics Inc.

HLS
Rangering i aksjer #22602
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm,... HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
Aksjekurs
$2.75
Sist synkronisert: 2026-08-21
Markedsverdi
$86.08M
Endring (1 dag)
-3.85%
Endring (1 år)
-27.06%
Land
CA
Handel HLS Therapeutics Inc. (HLS)

Kategori

Utbytteavkastning for HLS Therapeutics Inc. (HLS)
HLS Therapeutics Inc. (aksjesymbol: HLS) sin utbytteavkastning (TTM) per 2026 er: 0
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for HLS Therapeutics Inc. (HLS) fra 2026 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
År Utbytteavkastning Endre
Ikke nok data for de angitte datoene.
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter